Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543118 | 1.00 | ATM (0.42) | ATMF2PRSS1PRSS2PRSS3 | |
| SCHEMBL29285127 | 0.91 | ATM (0.37) | ATMF2PRSS1PRSS2PRSS3 | |
| SCHEMBL425737 | 0.89 | — | — | |
| SCHEMBL28439266 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL11162708 | 0.87 | — | — | |
| Water SCHEMBL8681204 | 0.87 | — | — | |
| SCHEMBL28681081 | 0.86 | ATM (0.39) | ATMF2PRSS1PRSS2PRSS3 | |
| SCHEMBL22229916 | 0.86 | ATM (0.39) | ATMF2PRSS1PRSS2PRSS3 | |
| SCHEMBL20241327 | 0.86 | ATM (0.39) | ATMF2PRSS1PRSS2PRSS3 | |
| SCHEMBL28592016 | 0.86 | ATM (0.39) | ATMF2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317955-A | N- (4-aminocyclohexyl) pyrimidine-4-carboxamide as CD38 inhibitor | 塞里文斯股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024056077-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-21 | — | — | WO | disclosed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-111918863-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-111094255-B | Compounds having cyclic structures | 第一三共株式会社 | 2023-10-03 | — | — | CN | disclosed |
| CN-115667259-A | Condensed ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-115298170-A | Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions | 诺华股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115297930-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-108290853-B | Fumagillol derivatives and polymorphs thereof | 辛德弗雷克斯公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3526210-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| CN-110072857-A | 1, 3-disubstituted cyclobutanone or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-07-30 | — | — | CN | disclosed |
| WO-2018068283-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2018-04-19 | — | — | WO | disclosed |
| CN-103282025-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107428733-A | CD38 inhibitor and treatment method | 葛兰素史克知识产权第二有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-104876927-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2017-06-23 | — | — | CN | disclosed |
| CN-104906100-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2015-09-16 | — | — | CN | disclosed |
| CN-104876927-A | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LAB | 2015-09-02 | — | — | CN | disclosed |
| CN-102448959-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE BAHAMAS LTD | 2015-06-17 | — | — | CN | disclosed |
| WO-2010032875-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | ATM 4722/4885F2 399/4885PRSS1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.